Compare McKesson Corporation (MCK) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs TJX Companies Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is the larger of the two by market cap, and TJX Companies Inc pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and TJX Companies Inc for 97 Days on average.
| MCK | TJX | |
|---|---|---|
Market Cap | $108.46B | $152.62B |
Volume | 712,607 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $168.41 |
52-Week Low | $725.17 | $122.84 |
Typical Hold Time | 74 Days | 97 Days |
Enterprise Value | $115.00B | $160.93B |
Dividend Yield | 0.4% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
TJX trades at $138.75, down slightly by 0.04% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growing from $48.5B in 2022 to $56.4B in 2025, and net income margin expanding to 8.63%. Recent quarters have consistently beaten EPS expectations, and analysts project a consensus price target of $174.15, implying 28% upside. The stock is supported by robust cash flow from operations of $6.12B in 2025 and a healthy balance sheet with $5.34B in cash.
The outlook for TJX is positive, driven by earnings growth, market share gains in off-price retail, and Wall Street's strong buy consensus. Key risks include competitive pressures, consumer spending volatility, and elevated valuation multiples. The stock presents a compelling opportunity for growth-oriented investors, though near-term technical overbought conditions warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
